文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Polo-like kinase 1 促进了 Pten 肿瘤抑制因子诱导的前列腺癌的形成。

Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.

机构信息

Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907; Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907.

Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907; Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907.

出版信息

J Biol Chem. 2011 Oct 14;286(41):35795-35800. doi: 10.1074/jbc.C111.269050. Epub 2011 Sep 2.


DOI:10.1074/jbc.C111.269050
PMID:21890624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3195584/
Abstract

Loss of the tumor suppressor Pten (phosphatase and tensin homolog deleted on chromosome 10) is thought to mediate the majority of prostate cancers, but the molecular mechanism remains elusive. In this study, we demonstrate that Pten-depleted cells suffer from mitotic stress and that nuclear function of Pten, but not its phosphatase activity, is required to reverse this stress phenotype. Further, depletion of Pten results in elevated expression of Polo-like kinase 1 (Plk1), a critical regulator of the cell cycle. We show that overexpression of Plk1 correlates with genetic inactivation of Pten during prostate neoplasia formation. Significantly, we find that elevated Plk1 is critical for Pten-depleted cells to adapt to mitotic stress for survival and that reintroduction of wild-type Pten into Pten-null prostate cancer cells reduces the survival dependence on Plk1. We further show that Plk1 confers the tumorigenic competence of Pten-deleted prostate cancer cells in a mouse xenograft model. These findings identify a role of Plk1 in facilitating loss of Pten-induced prostate cancer formation, which suggests that Plk1 might be a promising target for prostate cancer patients with inactivating Pten mutations.

摘要

抑癌基因 Pten(10 号染色体缺失的磷酸酶及张力蛋白同源物)缺失被认为介导了大多数前列腺癌,但其中的分子机制仍难以捉摸。在这项研究中,我们证实了 Pten 缺失的细胞遭受有丝分裂应激,且 Pten 的核功能(而非其磷酸酶活性)对于逆转这种应激表型是必需的。此外,Pten 的缺失导致 Polo 样激酶 1(Plk1)的表达上调,Plk1 是细胞周期的关键调控因子。我们发现,Plk1 的过表达与前列腺肿瘤形成过程中 Pten 的遗传失活相关。重要的是,我们发现升高的 Plk1 对于 Pten 缺失细胞适应有丝分裂应激以存活至关重要,并且将野生型 Pten 重新引入 Pten 缺失的前列腺癌细胞中可降低对 Plk1 的存活依赖性。我们进一步发现 Plk1 赋予了 Pten 缺失的前列腺癌细胞在小鼠异种移植模型中的致瘤能力。这些发现确定了 Plk1 在促进 Pten 缺失诱导的前列腺癌形成中的作用,这表明 Plk1 可能成为具有失活 Pten 突变的前列腺癌患者的一个有希望的治疗靶点。

相似文献

[1]
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.

J Biol Chem. 2011-9-2

[2]
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Protein Cell. 2012-3-23

[3]
Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle.

J Biol Chem. 2014-5-16

[4]
Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.

FASEB J. 2005-4

[5]
Phospho PTEN mediated dephosphorylation of mitotic kinase PLK1 and Aurora Kinase A prevents aneuploidy and preserves genomic stability.

Med Oncol. 2023-3-17

[6]
PTEN regulates PLK1 and controls chromosomal stability during cell division.

Cell Cycle. 2016-9-16

[7]
Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.

Mol Cell Biol. 2014-7-21

[8]
Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Mol Cell Biol. 2015-12

[9]
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?

Genes (Basel). 2019-3-11

[10]
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.

J Biol Chem. 2015-1-23

引用本文的文献

[1]
Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery.

Cancer Gene Ther. 2025-5-16

[2]
PLK1 phosphorylates WRN at replication forks.

J Pharmacol Exp Ther. 2025-2

[3]
MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.

Cancer Res Commun. 2025-2-1

[4]
Synthetic lethal approaches to target cancers with loss of PTEN function.

Genes Dis. 2023-11

[5]
Cyclers' kinases in cell division: from molecules to cancer therapy.

Cell Death Differ. 2023-9

[6]
A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer.

Front Mol Biosci. 2023-5-9

[7]
Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinoma.

J Cancer Res Clin Oncol. 2023-8

[8]
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.

Cancer Res. 2023-1-18

[9]
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.

Eur J Med Chem. 2022-1-5

[10]
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.

J Med Chem. 2021-7-22

本文引用的文献

[1]
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.

Prostate. 2011-1-12

[2]
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.

Cell. 2011-1-21

[3]
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

Clin Cancer Res. 2010-8-3

[4]
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Nat Rev Drug Discov. 2010-8

[5]
Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

EMBO Rep. 2010-6-25

[6]
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).

Eur J Cancer. 2010-5-13

[7]
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.

Mol Cancer Ther. 2010-1-26

[8]
Pten in stromal fibroblasts suppresses mammary epithelial tumours.

Nature. 2009-10-22

[9]
Principles of cancer therapy: oncogene and non-oncogene addiction.

Cell. 2009-3-6

[10]
Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development.

Curr Opin Cell Biol. 2008-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索